- Conditions
- Visual Impairment, Myopia, Hyperopia, Astigmatism
- Interventions
- With Try-on glasses
- Device
- Lead sponsor
- EyeQue Corp.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Newark, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 242
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Amblyopia, Strabismus
- Interventions
- Pediatric Vision Scanner eye scan
- Device
- Lead sponsor
- Rebiscan, Inc.
- Industry
- Eligibility
- 6 Months to 6 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Retinal Detachment
- Interventions
- Ultrasound, Ophthalmology Assessment
- Device · Other
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Visual Perception
- Interventions
- Psychophysical task
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetic Macular Edema, Cataract
- Interventions
- Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetic Retinal Disease
- Interventions
- Visual Acuity, Reading Speed, Visual Field testing, Contrast sensitivity, Electroretinography (ERG) and pupillography in light- and dark-adapted states, Ultrawide field-color photograph, Ultrawide field-Fluorescein angiogram, Optical coherence tomography, Optical coherence tomography- Angiography
- Diagnostic Test · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 6
- States / cities
- Augusta, Georgia • Boston, Massachusetts • Detroit, Michigan + 3 more
- Conditions
- Vision Loss Night, Vision Disorders
- Interventions
- 0.75% Phentolamine Ophthalmic Solution, Placebo
- Drug
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 16 more
- Conditions
- Hyperopia, Myopia
- Interventions
- 1% EXP039, Saline control
- Drug · Other
- Lead sponsor
- Canyon City Eyecare
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Azusa, California
- Conditions
- Refractive Error
- Interventions
- FID122819 contact lenses, Stenfilcon A contact lenses
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Longwood, Florida • Maitland, Florida • Johns Creek, Georgia
- Conditions
- Blindness, Leber Congenital Amaurosis 10, Vision Disorders, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration
- Interventions
- Not listed
- Lead sponsor
- Editas Medicine, Inc.
- Industry
- Eligibility
- 3 Years to 99 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
- Conditions
- Corneal Edema Secondary to Corneal Endothelial Dystrophy
- Interventions
- DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
- Procedure · Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cataract
- Interventions
- AcrySof® Toric IOL
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Dorzolamide-timolol
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Interventions
- CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
- Drug · Device
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Arcadia, California • Chicago, Illinois • Lexington, Kentucky + 5 more
- Conditions
- Pseudophakia
- Interventions
- Visual Acuity, Defocus Curve, Halo and Glare testing, Patient Questionnaires
- Diagnostic Test · Other
- Lead sponsor
- Berkeley Eye Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Not listed
- Lead sponsor
- Julia Haller
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Amblyopia
- Interventions
- Video Game Vision Training, Perceptual Learning, Occlusion Therapy
- Behavioral
- Lead sponsor
- Nova Southeastern University
- Other
- Eligibility
- Not listed
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
- Interventions
- Gene Therapy product-MCO-010
- Biological
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
- Conditions
- Aphakia, Presbyopia
- Interventions
- CPO Pro IOL, CPO IOL, Cataract Surgery
- Device · Procedure
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Torrance, California • Bloomfield Hills, Michigan • Kansas City, Missouri + 5 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Valeda Light Delivery System, Valeda Light Delivery System Sham Mode
- Device
- Lead sponsor
- LumiThera, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 7 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
- Interventions
- Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
- Other · Diagnostic Test · Genetic
- Lead sponsor
- University of Rhode Island
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more